AMP as a Better Delivery System of Adenosine
Information source: Vanderbilt University
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Ischemia
Intervention: Adenosine (Drug); Adenosine Mono Phosphate (AMP) (Drug)
Phase: N/A
Status: Suspended
Sponsored by: Vanderbilt University Official(s) and/or principal investigator(s): Italo Biaggioni, M.D., Principal Investigator, Affiliation: Vanderbilt University
Summary
Adenosine and AMP are substances normally present in the body. Adenosine is also given for
the treatment of some heart rhythm problems and may be used to reduce heart damage during
heart attacks. The problem in using adenosine is that it is taken up by cells and,
therefore, very little of the adenosine we give by vein or in the artery actually reaches
the tissue. We propose to use AMP as a way to improve delivery of adenosine. AMP is
inactive by itself, but is converted to adenosine in tissue. We hope that by giving AMP we
will increase levels of adenosine in tissue. To see if this is true, we will give either
adenosine or AMP into the forearm artery while we measure how much adenosine reaches the
forearm tissue.
Clinical Details
Official title: Use of AMP to Improve Tissue Delivery of Adenosine
Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)
Primary outcome: Interstitial adenosine levelsForearm blood flow
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Healthy volunteers
- Age 18-65
- Non smokers
Exclusion Criteria:
- Smokers
- Any chronic disease
Locations and Contacts
Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States
Additional Information
Starting date: October 2003
Last updated: February 2, 2015
|